Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis

References

• Duan ZH, Pan FM, Zeng Z, Zhang TC, Wang S, Li GX, . The FCGR2B rs10917661 polymorphism may confer susceptibility to ankylosing spondylitis in Han Chinese: a case-control study. Scand J Rheumatol 2012;41:219–22.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl 3):iii8–18.
   PubMedGoogle Scholar
• Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051–4.
   PubMed Web of Science ®Google Scholar
• Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007;104:18660–5.
   PubMed Web of Science ®Google Scholar
• Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526–34.
   PubMed Web of Science ®Google Scholar
• Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, . The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046–55.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, . IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479–90.
   PubMed Web of Science ®Google Scholar
• Trajkovic V, Sweet MJ, Xu D. T1/ST2 – an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004;15:87–95.
   PubMed Web of Science ®Google Scholar
• Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, . T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930–5.
   PubMed Web of Science ®Google Scholar
• Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, . Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011;26:1132–9.
   PubMed Web of Science ®Google Scholar
• Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, . Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 2010;49:520–7.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011;30:825–30.
   PubMed Web of Science ®Google Scholar
• Manetti M, Ibba-Manneschi L, Liakouli V, Guiducci S, Milia AF, Benelli G, . The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010;69:598–605.
   PubMed Web of Science ®Google Scholar
• Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
   PubMed Web of Science ®Google Scholar
• Han GW, Zeng LW, Liang CX, Cheng BL, Yu BS, Li HM, . Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 2011;30:1583–8.
   PubMed Web of Science ®Google Scholar
• Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010;37:2006–13.
   PubMed Web of Science ®Google Scholar
• Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012;58:6–9.
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011;11:75–80.
   PubMed Web of Science ®Google Scholar
• Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009;123:1047–54.
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, . IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339–46.
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007;37:2779–86.
   PubMed Web of Science ®Google Scholar
• Tajima S, Bando M, Ohno S, Sugiyama Y, Oshikawa K, Tominaga S, . ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis. Exp Lung Res 2007;33:81–97.
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Ceccarelli C, Romano E, Bellando-Randone S, Conforti ML, . Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 2011;70:1876–8.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328–32.
   PubMed Web of Science ®Google Scholar
• Isomäki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1693–702.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011;30:231–7.
   PubMed Web of Science ®Google Scholar